614 related articles for article (PubMed ID: 22486873)
1. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
[TBL] [Abstract][Full Text] [Related]
3. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy.
Blonski W; Vela MF; Castell DO
J Clin Gastroenterol; 2009 Oct; 43(9):816-20. PubMed ID: 19398927
[TBL] [Abstract][Full Text] [Related]
6. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
7. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
[TBL] [Abstract][Full Text] [Related]
8. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus.
Emerenziani S; Sifrim D; Habib FI; Ribolsi M; Guarino MP; Rizzi M; Caviglia R; Petitti T; Cicala M
Gut; 2008 Apr; 57(4):443-7. PubMed ID: 17766596
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
Becker V; Bajbouj M; Waller K; Schmid RM; Meining A
Aliment Pharmacol Ther; 2007 Nov; 26(10):1355-60. PubMed ID: 17900268
[TBL] [Abstract][Full Text] [Related]
10. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
[TBL] [Abstract][Full Text] [Related]
11. The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburn.
Frazzoni M; Conigliaro R; Mirante VG; Melotti G
Neurogastroenterol Motil; 2012 Feb; 24(2):141-6, e87. PubMed ID: 21988704
[TBL] [Abstract][Full Text] [Related]
12. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
[TBL] [Abstract][Full Text] [Related]
13. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
Iwakiri K; Sano H; Tanaka Y; Kawami N; Umezawa M; Futagami S; Hoshihara Y; Nomura T; Miyashita M; Sakamoto C
Digestion; 2010; 82(3):156-61. PubMed ID: 20588027
[TBL] [Abstract][Full Text] [Related]
15. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease.
Slaughter JC; Goutte M; Rymer JA; Oranu AC; Schneider JA; Garrett CG; Hagaman D; Vaezi MF
Clin Gastroenterol Hepatol; 2011 Oct; 9(10):868-74. PubMed ID: 21782769
[TBL] [Abstract][Full Text] [Related]
16. Combined esophageal multichannel intraluminal impedance and pH monitoring (MII -pH) in the diagnostics and treatment of gastroesophageal reflux disease and its complications.
Masiak W; Wallner G; Wallner J; Pedowski T; Solecki M
Pol Przegl Chir; 2011 Sep; 83(9):488-96. PubMed ID: 22166737
[TBL] [Abstract][Full Text] [Related]
17. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
Weigt J; Kandulski A; Büsch F; Malfertheiner P
Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
[TBL] [Abstract][Full Text] [Related]
18. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
[TBL] [Abstract][Full Text] [Related]
20. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder.
Izawa S; Funaki Y; Iida A; Tokudome K; Tamura Y; Ogasawara N; Sasaki M; Kasugai K
Digestion; 2014; 89(1):61-7. PubMed ID: 24458115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
